Form 4: Catalyst Pharmaceuticals Chief Commercial Officer Acquires Shares and Stock Units

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, acquired 137,553 stock options and 16,809 restricted stock units on November 21, 2024.

Summary

• Jeffrey Del Carmen, the Chief Commercial Officer of Catalyst Pharmaceuticals, has reported the acquisition of 137,553 stock options and 16,809 restricted stock units.
• The stock options have an exercise price of $21.12 and vest in three equal tranches on November 21, 2025, 2026, and 2027.
• The restricted stock units represent a contingent right to receive one share of common stock upon vesting.
• Following these transactions, Mr. Del Carmen directly owns 941,572 stock options and 958,381 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed positively as it aligns executive interests with company performance. There are no negative implications.

Positives

• The acquisition of stock options and restricted stock units by a key executive like the Chief Commercial Officer can be seen as a positive sign of confidence in the company's future performance.
• The vesting schedule of the stock options encourages long-term commitment from the executive.

Industry Context

This is a routine filing related to executive compensation and is common in the pharmaceutical industry. It reflects standard practice for aligning executive interests with shareholder value through equity-based incentives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of compensation for executives in the pharmaceutical industry, similar to companies like Biogen, Amgen, and Gilead Sciences.
• The vesting schedule of the options is typical, designed to incentivize long-term performance and retention, which is a standard practice across the sector.
• The exercise price of $21.12 is a specific detail related to the company's stock price at the time of the grant and is not directly comparable to other companies without considering their individual stock valuations.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a key executive can positively impact shareholder confidence.
• The vesting schedule of the options encourages long-term commitment from the executive, which can benefit the company and its stakeholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, Form 4, CPRX, Jeffrey Del Carmen